Bristol-Myers, Otsuka Hit With Failure-To-Warn Suit For Abilify

Law360, Los Angeles (August 22, 2014, 8:29 PM EDT) -- A New York user of the antipsychotic Abilify accused Bristol-Myers Squibb Co. and Otsuka American Pharmaceutical Inc. in New York court of failing to warn doctors that the drug makes children nearly 10 times more likely to develop adult-onset diabetes.

The suit claims that the average recommended dose of Abilify increases a child’s risk for Type II diabetes 7.72 times above normal, but Bristol-Myers and Otsuka did not update their labeling to tell doctors about the severity of the risk. 

“In fact, the labeling for Abilify entirely fails to quantify the risk to pediatric plaintiffs,” the complaint said.

Plaintiff Cheyenne Beth...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!